Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary

November 14, 2023

London Stock Exchange GB Health Care Biotechnology earnings 29 min

Earnings Call Speaker Segments

Operator

operator
#1

Hello, and welcome to the conference call covering Palatin's operating results for the first quarter of fiscal year 2024. Right now, everyone is in a listen-only mode. After the formal presentation, there will be a question-and-answer session. <<operator_script>> Please be aware that this conference is being recorded. Before our remarks get underway, I want to note that anything Palatin states which is not a historical fact could be a forward-looking statement. Such statements rest on assumptions that might or might not turn out to be accurate, and actual results could differ materially from what is anticipated because of the various risks and uncertainties covered in the company's latest filings with the Securities and Exchange Commission. As you evaluate these forward-looking statements by Palatin's prospects, please weigh those risks and uncertainties carefully. I'd now like to hand the call over to our host, Dr. Carl Spana, Palatin's President and Chief Executive Officer. Please go ahead.

Carl Spana

executive
#2

Thanks. Morning, everyone, and thanks for joining the Palatin call covering the first quarter of fiscal year 2024. I'm Dr. Carl Spana, CEO and President of Palatin. Joining me today is Steve Wills, Palatin's Executive Vice President, Chief Financial Officer and Chief Operating Officer. At this point I'll hand things over to Steve, who'll walk through the financial and operating updates. Steve?

Steve Wills

executive
#3

Thanks, Carl, and welcome, everyone. Turning to the non-financial highlights for Vyleesi, our commercial product approved for premenopausal women to treat HSDD — that's hypoactive sexual desire disorder. As we've said before, the aim is to show commercial product value in the marketplace, with the objective of re-licensing the U.S. rights, and possibly even the global rights, to a committed women's healthcare company. Fosun Pharma, Palatin's licensee for Vyleesi in China, reported its first sale in the Hainan Province of China. Kwangdong Pharmaceuticals, Palatin's licensee for Vyleesi in South Korea, finished enrollment in its Phase 3 clinical trial assessing the efficacy and safety of Vyleesi in premenopausal women with HSDD. Data is currently expected by calendar year end 2023, with a possible regulatory submission in the first half of calendar 2024. Palatin formed a strategic partnership with UpScriptHealth, a leading direct-to-consumer telemedicine company that provides telemedicine services to pharmaceutical and medical technology companies. On operations, specifically for Vyleesi, for the fiscal first quarter ended September 30, 2023, gross product sales of $4.6 million rose 11% versus the prior quarter and rose 100% versus the comparable quarter last year. Net product revenue of $2.1 million rose 20% versus the prior quarter and rose 142% versus the comparable quarter last year.

Steve Wills

executive
#4

Prescriptions dispensed in total rose 14% versus the previous quarter, and they were up 88% against the same quarter a year earlier. Refill rates, reimbursement from commercial insurance, and net revenue for each prescription dispensed kept showing positive and impactful results and trends, both against the prior quarter and against the comparable quarter last year. Vyleesi posted its seventh quarter in a row of double-digit growth across all metrics, both the significant ones and some that are not as significant. Importantly, quarterly net product revenue for Vyleesi keeps coming in above Vyleesi’s quarterly operating expenses. Turning to overall operations for the fiscal — for the first quarter ended September 30, 2023. On revenue, total revenue is made up of gross product sales of Vyleesi, net of expenses, allowances and accruals, plus license and contract revenue. As I said, Vyleesi gross product sales to pharmacy distributors for the quarter ended September 30, 2023 came to $4.6 million, with net product revenue of $2.1 million. That compares with gross product sales of $2.3 million — looks like that was a double — and net product revenue of a little under $1 million for the comparable quarter last year. Gross product sales were up 100%. Yes, that would be a double. And net product revenue rose 142% over the comparable quarter of last year.

Steve Wills

executive
#5

Now on operating expenses. For the quarter that ended September 30, 2023, total operating expenses came in at $8.2 million, versus $9.6 million in the same quarter a year earlier. That drop was primarily tied to an overall reduction in spending on our MC — that stands for melanocortin — programs, and secondarily to a general decline in selling expenses for Vyleesi, and to some degree to lower cost of product sold stemming from the sale of fully reserved Vyleesi inventory. Turning to cash flows. Net cash used in operations at Palatin for the quarter ended September 30, 2023, was $5.9 million, against net cash used in operations of $8.6 million during the same period in 2022. The lower net cash used in operations largely reflects a reduced net loss, offset by changes in working capital. Now for net loss. Palatin recorded a net loss of $5.9 million, or $0.48 per basic and diluted common share, for the quarter ended September 30, 2023, versus a net loss of $8.3 million, or $0.86 per basic and diluted common share, in the same quarter of 2022. Pardon me — I've got a bit of a lingering cough. On cash position. As of September 30, 2023, cash, cash equivalents and marketable securities at Palatin totaled roughly $5.5 million, plus $1.3 million in accounts receivables, compared with $11 million plus $2.9 million in accounts receivables as of June 30, 2023.

Steve Wills

executive
#6

As of September 30, 2023, we had $5.5 million in cash, cash equivalents and marketable securities — and that figure excludes $4.5 million in net proceeds from the Registered Direct Offering, which closed in October 2023. Our view is that our current cash, cash equivalents, marketable securities and accounts receivables should be enough to cover anticipated operating expenses and disbursements into the first half of calendar year 2024. With that, I’ll hand things back to Carl.

Carl Spana

executive
#7

Thank you, Steve. As you know, we're focused on establishing the melanocortin system as a target for safe and effective medicines to treat inflammatory and autoimmune diseases, and on developing a pipeline of highly effective drugs with unparalleled safety. We have three active clinical programs based on melanocortin agonist, with multiple new programs ready to advance into clinical development pending resources. All of these are coming from our highly productive research activities. As previously reported, we have completed patient enrollment in the PL9643 MELODY-1, Phase 3 study for dry eye disease. As a reminder, PL9643 is a topically delivered melanocortin agonist that works by resolving inflammation on the ocular surface that is the cause or a key cause of dry eye disease. We've also conducted an interim analysis of initial 120 patients enrolled in MELODY-1, which showed statistical separation for clinical efficacy across multiple signs and symptoms of dry eye disease. Importantly, PL9643 has excellent ocular safety and tolerability. With the last patient about to complete randomized treatment, we are working to have the top line data by year end. We believe the emerging efficacy and tolerability profile of PL9643 gives the potential to be a leading treatment for dry eye disease.

Carl Spana

executive
#8

Turning now to our Phase 2 trial of oral PL8177 — that's a selective melanocortin-1 receptor agonist being tested in ulcerative colitis patients — we remain on schedule to conduct an interim review of the clinical data during the first quarter of 2024. Backing the development of oral PL8177 are preclinical work showing that, when given in a disease model, oral PL8177 leads the diseased colon to return to a healthy condition and to clear the pathological inflammation. By resolving inflammation instead of merely blocking it, we open up the prospect of achieving efficacy together with safety when treating colitis and inflammatory bowel disease. And our BREAKOUT study — a Phase 2 open-label trial in diabetic patients who have kidney disease — likewise stays on track to deliver top line data in the first part of 2024. I want to spend a moment drawing attention to two fresh clinical studies that we expect to launch in the first quarter of calendar 2024. The first of these is a Phase 2 trial testing a novel formulation that pairs bremelanotide, a melanocortin agonist, with a phosphodiesterase-5 inhibitor — drugs in that class include Vyleesi, I'm sorry, include Cialis and Viagra. This builds on our commercial work in sexual dysfunction. Roughly 35% of men with erectile dysfunction either fail or respond inadequately to PDE5 inhibitor treatment, which represents a sizable underserved market.

Carl Spana

executive
#9

For these failure patients, the sole treatment choices are highly invasive—things like penile injections or penile implants. Clinical trials we ran earlier demonstrated synergistic effects when bremelanotide is combined with a PDE-5 inhibitor for treating erectile dysfunction. A second clinical study is going to assess a melanocortin-4 receptor agonist in obese patients who are taking GLP-1 agonists. The GLP-1 agonist, for products such as Ozempic or Wegovy. Such drugs are in use, and you hear about them on the news constantly. These drugs represent the current standard of care when it comes to treating obese patients. Since drug treatment for obesity is now established and expanding quickly, our belief is that the treatment goal will shift away from driving weight loss toward overall weight management. That will call for a variety of drugs with differing mechanisms of action affecting not only weight loss but, importantly, weight loss maintenance. We strongly believe that drugs targeting the melanocortin system will form an important part of the future of obesity. Treatment and overall weight management. Given our extensive experience in designing and developing melanocortin agonists for treating obesity, including two clinical studies, we are well positioned to lead in the development of melanocortin-based therapeutics.

Carl Spana

executive
#10

Before we get to questions, here are a few operating highlights. I want to say again how pleased we are with Vyleesi: seven consecutive quarters of double-digit growth across every value metric. In particular, net product revenue rose 20% versus the prior quarter, and prescriptions dispensed were up another 14% from the quarter before. We're also very excited that Vyleesi's quarterly net product revenue keeps surpassing its quarterly operating expenses, because as we said, we plan to launch two new programs with Phase 2 clinical studies beginning in the first quarter of calendar 2024, with data readouts in 2024 as well. Those two studies are, as we just mentioned, first, one evaluating the co-formulation of bremelanotide with a PDE-5 inhibitor in erectile dysfunction patients who have failed first-line therapy. In other words, Viagra or Cialis isn't working for them, and they need to move to more aggressive therapy. Second, we'll evaluate adding the melanocortin-4 agonist bremelanotide to obese patients who are taking a GLP-1 agonist. Our ocular programs keep making impressive advances. Our MELODY-1 Phase 3 DED study, the dry eye study, is fully enrolled, with data coming at the end of the year.

Carl Spana

executive
#11

We’re quite enthusiastic about the product profile that’s taking shape for PL9643, which stands apart strongly from therapies available today. Ocular tolerability has been excellent in our view, and we believe broad efficacy will be seen across a range of signs and symptoms, plus we’re genuinely excited that it could also turn into a leading therapy for dry eye disease. And last, PL9588 — we’ve discussed this before — is a novel melanocortin agonist aimed at glaucoma. At this point we remain on schedule to submit an IND around the close of the first half of 2024, and after that proceed into Phase 2 clinical studies. Thank you for tuning in to the Palatin first quarter fiscal year 2024 call. More details about our science and clinical programs can be found on our website, www.palatin.com. Additional information about Vyleesi is also available at the Vyleesi website, vyleesi.com. Steve and I truly want to express our thanks for your support and your interest, and we’ll now open the call for questions.

Operator

operator
#12

Sure. We'll now move into a question-and-answer session. <<operator_script>> Our first question today comes from Joe Pantginis at H.C. Wainwright.

Joe Pantginis

analyst
#13

Hi everyone, thanks so much. So Carl, first off, I'd like to ask about how the logistics will work around the news flow for MELODY-1 that's coming up. So when you mention top line data late this year and final data in the first quarter, I suppose I was hoping to get a sense of what you expect to show on the top line data side?

Carl Spana

executive
#14

Absolutely. So we’ll just be concentrating on the study’s primary endpoints along with overall safety. I mean, there will be a sign and a symptom. There will most likely be tear breakup time or inferior corneal fluorescein staining. Those kinds of measures will be for your assigned endpoint, and then for your symptom, and most likely ocular pain.

Joe Pantginis

analyst
#15

And it’s going to be…

Carl Spana

executive
#16

Please continue.

Joe Pantginis

analyst
#17

Sorry about that. You prefer — will we be receiving, say, figures at the top line, or is it more that, like, either you hit those endpoints and then we’ll have them at the top line, or are we actually aiming toward figures at the top line side of things?

Carl Spana

executive
#18

Steve and I are both fond of figures, so we release figures.

Steve Wills

executive
#19

Numbers will be involved.

Carl Spana

executive
#20

If we reach that goal — and I believe we will — then we're going to be pushing it and promoting it.

Joe Pantginis

analyst
#21

Understood. Understood. And then, look, that recent preclinical data you released on combining bremelanotide with a GLP-1 for obesity is exciting. And as you mentioned, this is everything we're hearing about in the news right now. So I'm hoping to get a bit more detail on the clinical and regulatory pathway for this combination. What will the studies look like at the outset, and where do you think you can position yourself as the competitive landscape keeps shifting, and are there particular patients you might target. And then perhaps some added color when you talk about sustaining the weight loss, because as things stand today, with these GLP-1s, you essentially need to stay on them for life? So I'd like to get a sense of how BMT might contribute to that?

Carl Spana

executive
#22

Alright, let me pull back for a moment and look at this from a broader perspective, since what we're talking about is a 20-year process. Not for us specifically, I mean weight loss management treatment. It will unfold much the way hypertension did. Multiple therapeutic classes will come into the market, and each one will have its own niche, offering its own risk-reward profile and benefits. The real objective now becomes: how do we help most of the patients who walk in actually hit their weight loss goals and stay there, because as a society we're the ones footing the bill. And we won't see the benefits. If you drop weight over six or 10 months and, say, take off that 50 pounds. If it returns within six months, that's not good, correct? We spent a lot of money and we don't capture the overall long-term benefits. All those wonderful things Novo's <<inaudible>> reporting about their work on reducing cardiovascular risk, overall mortality, those happen because you keep weight off. It isn't merely the weight loss process itself.

Carl Spana

executive
#23

So with that in mind, take bremelanotide as an example—that’s the one our upcoming study will examine against the backdrop of a GLP-1. It really serves as an initial step, correct? We’ve got the preclinical data. Some recent case studies were just reported involving melanocortin-4 agonists added onto tirzepatide or Wegovy treatment, and they showed you can genuinely boost weight loss by combining the two mechanisms without needing to raise that GLP-1 dose. That matters a great deal, because we hear plenty about these GLP-1 drugs, but what we don’t really hear about is what happens when you actually start talking to patients. Many of them take it because they want to shed pounds. They aren’t taking them because they’re having a great experience on them. So combining mechanisms gives a clinician the chance to essentially modulate the side effects, making sure each patient receives the treatment they need and that they reach their goals. Now let’s turn to the other side, maintenance. You guys probably aren’t aware of this, but we had a collaboration with AstraZeneca a while back looking at melanocortin for weight loss and then particularly for weight loss maintenance.

Carl Spana

executive
#24

But within that, we actually have Palatin compounds that were tested in weight loss models. And what's really interesting there is we were able to show that with melanocortin, you don't have to administer a huge amount of melanocortin to actually keep weight loss going. So if you take an obese animal, you take them through the weight loss process, and now they're in a state where they're in a weight loss state. One of the things you're up against, whether it's an animal or a human, is that your body wants to return, right? You've got — you want to take in more calories, your skeletal muscles don't function as well, you're burning fewer calories. So you have to combat that process. It turns out that the melanocortin mechanism may be very, very well suited to that. We observed that it was one-sixth of the dose required to maintain versus cause weight loss. So we think there's a very, very good opportunity there, and that's going to be very key to the overall success of weight management. So we think about it more globally and where we can play, there are going to be multiple pockets where we can play, from being an addition to maybe GLP-1 <<inaudible>> therapy so that patients lose more weight without having to go up in dose or have more tolerable effects, weight loss maintenance patients that aren't tolerating the GLP-1s are contraindicated.

Carl Spana

executive
#25

There are a lot of areas where a melanocortin can have an impact, and I'd say it's likely among the strongest mechanisms, since it was one of the earliest mechanisms that we — that really developed, or was the origin of the idea of addressing weight loss from a pharmaceutical standpoint.

Joe Pantginis

analyst
#26

Those colors are really helpful. Thanks very much, Carl.

Operator

operator
#27

Michael Higgins from Ladenburg Thalmann has the next question.

Farhana Sakloth

analyst
#28

Hey, good morning. Farhana <<inaudible>> here, speaking for Michael. Congrats on the ongoing progress this quarter, and we’re really eager for the MELODY data. Just wanted to follow up on what you were asked earlier about the MELODY readout. So I understand that the data in the fourth quarter will include the primary endpoint and safety. But could you give us some more detail on what we can see in the final data readout that’s coming in the first quarter next year?

Carl Spana

executive
#29

Sure. Look, I mean, there are probably 20 different endpoints that we look at in addition to all of the safety endpoints as well. That so you’ll see the full data set as quickly as we can get it done and out. That can be, I mean, it’s not appropriate for a press release, so that would normally found a publication or on presentations but or maybe we’ll have a conference call to go over it. You’ll also look at any of the sub-analysis that we may do on various types of patients. These are very data rich studies. So I mean, I’m sure we’ll be analyzing this data for the next six months to see what comes out. But in general, we will try to get out as quickly as we can the full dataset, all of the endpoints that are there, both the primary, key secondaries and then the corresponding secondaries and then exploratory endpoints as well. And then there’ll be a variety of signs and symptoms everything from all of the different staining using either fluorescein or Lissamine green that we’re using or the various symptom endpoints, ocular pain, dryness, stinging, burning all those types of standard types of things that are evaluated in dry eye studies.

Carl Spana

executive
#30

We’ll aim to be as transparent as possible. The one caveat I’d add is that it’s reasonable to assume that with a positive study, we might be in certain discussions, and as part of that, there may be things we don’t want to disclose—but apart from that, we’ll try to be as transparent as we can.

Farhana Sakloth

analyst
#31

All right, great. And then regarding Vyleesi, about out-licensing or selling it in the U.S., how confident are you that you can get this done, maybe by this spring?

Carl Spana

executive
#32

So. After we posted 3 straight quarters of double-digit growth, we felt fairly confident at 7. That confidence has only grown stronger and broader. We don’t expect — well, actually, we do expect 8 consecutive quarters of double-digit growth, but we’re moving discussions forward, and we’re reasonably confident that we will transact on Vyleesi in the very near future.

Analyst

analyst
#33

Okay. Then a second follow-up regarding the GLP-1 program. Could you share any feedback about the trial design? And specifically, are you targeting any particular kind of obese patients, for example those with a minimum BMI or those who are refractory to GLPs?

Carl Spana

executive
#34

Okay. So these are individuals who are already receiving GLP therapy, in all likelihood tirzepatide. That means a combined GLP/GIP <<inaudible>>. You'd be seeking a BMI likely above 35. So these will be fairly obese individuals. We will — we definitely will do genetic profiling on these individuals, so we'll gain a complete picture of whatever mutations they carry in the <<inaudible>> pathways too. But we aren't stratifying based on that. What we're actually after is broader obesity. I think one thing we're truly seeking is simply melanocortin's shift now from a more specialized treatment for particular populations with genetic mutation into the broader obese population. And so this really is just the initial look at actually confirming how the two interact, because I think it's going to be important for the GLP-1s to actually hit their maximum potential, correct? And it's not that Lilly or Novo require any assistance from Palatin. But for them to actually hit their maximum potential, you're going to need to add them, you're going to need to add additional mechanisms to them, since not every patient can tolerate. You can't move, not every patient can move up in the dosing for those treatments.

Carl Spana

executive
#35

And if you speak with many patients, the side effects that dull some of the pleasure from not only eating food but also other activities people engage in can be troublesome, and many patients do get the GI side effects. So being able to reduce those and keep people on treatment so they truly lose the weight they need to lose is going to be key.

Farhana Sakloth

analyst
#36

Alright, I’ll take one more question and then rejoin the queue. Regarding bremelanotide in the BREAKOUT study, is the main aim to out-license it too? Or do you envision developing it yourselves?

Carl Spana

executive
#37

Okay, so there were a couple of goals here. The first was to examine — we think that in autoimmune anti-inflammatory kinds of disease, the melanocortin system is going to have a key part to play. This is one way to demonstrate just how wide that reach can be. That's why we've got a UC study, we've got the kidney work, and you've got the ocular studies currently underway. And it's also meant to back our out-licensing efforts. I don't really picture us going forward as a kidney-focused company. The point is genuinely to support out-licensing or ongoing use. Still, bear in mind that behind bremelanotide, across any of our programs, sits a broad portfolio of selective compounds targeting the different melanocortin receptors. So in many instances we're employing bremelanotide — potentially for obesity and the kidney studies, for instance — as proof of concept and proof of mechanism. Then, should opportunities arise for bremelanotide on its own, wonderful, we'll go after them or bring in third parties to assist. If not, it still supplies the evidentiary foundation for earlier compounds to advance into development and to feature in collaborations with bigger companies. And we're already witnessing that in other indications where we've generated prior data, and now the fact that we hold novel compounds is drawing in larger companies.

Analyst

analyst
#38

All right, excellent. I’ll rejoin the queue now. Thanks.

Operator

operator
#39

Michael Higgins has a follow-up question lined up for you.

Analyst

analyst
#40

Hello there.

Carl Spana

executive
#41

That's fine.

Farhana Sakloth

analyst
#42

For PL8177 in ulcerative colitis, do you have visibility into that data as it comes in? And if you do, is there anything you can share with us?

Carl Spana

executive
#43

So there is a blinded study — it isn’t open-label. Because of that, I’d rather not really comment on it publicly. I’ll just say we’re optimistic a signal will be there. Let’s leave it at that.

Analyst

analyst
#44

Alright, and my final question concerns the erectile dysfunction study. Could you walk us through your regulatory strategy for that combination? For instance, what patient counts are you planning for Phase 2 and Phase 3, and is there anything specific about how many refractory attempts with a single PDE-5…

Carl Spana

executive
#45

Okay, so broadly speaking, we'd stay with the existing guidance on this. What you'd want to see is a patient who has failed a PDE-5 inhibitor being at the maximum dose of that PDE-5 inhibitor, with proper instructions given. And then there would be a — we'd likely rely on the international index erectile function — specifically the erectile function subdomain score. So we'd examine — we'd classify patients according to the cutoff for that domain. I can't recall the precise figures offhand, but they are well established and widely published. Still, you've identified something important. One thing is that, as part of the regulatory process, as we move from a — from a — from the study we're currently running toward something more like a formal registration study, we'll need to reach final agreement with the agency regarding the exact definition of failure. But that ought to be fairly straightforward, as I mentioned, drawing on guidance that already exists, publications already available that use the international index erectile function, and confirming that patients were on a maximal dose with suitable education.

Analyst

analyst
#46

All right, and thanks a lot for all of those comments.

Carl Spana

executive
#47

That’s not a problem at all.

Operator

operator
#48

That brings the Q&A portion to a close. Carl will now take over for some final comments.

Carl Spana

executive
#49

Great. Steve and I want to thank you for joining us. Clearly, the questions from our analysts were excellent. We're grateful for their support too. We look forward to keeping all of you posted — Q4 is a big quarter for us, as it is for everyone, but we're genuinely excited about what we'll deliver over the coming couple of quarters. So, Steve, and I want to thank you. Have a great day and happy holidays.

Operator

operator
#50

That brings us to the end of today's conference, and you're free to drop off your lines now. Thanks for joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.